DelveInsight’s, “Hereditary Angioedema Pipeline Insight 2023” report provides comprehensive insights about 20+ companies and 30+ pipeline drugs in the Hereditary Angioedema pipeline landscape. It covers the Hereditary Angioedema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hereditary Angioedema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Hereditary Angioedema Pipeline Report

• DelveInsight’s Hereditary Angioedema pipeline report depicts a robust space with 20+ active players working to develop 30+ pipeline therapies for Hereditary Angioedema treatment.
• The leading companies working in the Hereditary Angioedema Market include BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, and others.
• Promising Hereditary Angioedema Pipeline Therapies in the various stages of development include DX-2930 – 300mg/2wk, Icatibant, Donidalorsen, STAR-0215, ADX-324, TAK-743 300 mg, and others.
• September 2023: KalVista Pharmaceuticals Ltd announced a study of phase 3 clinical trials for KVD900 600 mg. This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.
• September 2023: CSL Behring announced a study of phase 3 clinical trials for CSL312. This phase 3b study will evaluate long-term safety and efficacy of CSL312 (also known as garadacimab) when administered subcutaneously (SC).

 

Request a sample and discover the recent advances in Hereditary Angioedema Treatment Drugs @ Hereditary Angioedema Pipeline Report

 

In the Hereditary Angioedema pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Hereditary Angioedema clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Hereditary Angioedema Overview

Hereditary angioedema is a disorder characterized by recurrent episodes of severe swelling (angioedema). The most common areas of the body to develop swelling are the limbs, face, intestinal tract, and airway. Minor trauma or stress may trigger an attack, but swelling often occurs without a known trigger.

 

Find out more about Hereditary Angioedema Therapeutics Assessment @ Hereditary Angioedema Preclinical and Discovery Stage Products

 

Hereditary Angioedema Emerging Drugs Profile

• KVD900: KalVista Pharmaceuticals
• PHA121: Pharvaris
• BMN 331: BioMarin Pharmaceutical

 

Hereditary Angioedema Pipeline Therapeutics Assessment

There are approx. 20+ key companies which are developing the Hereditary angioedema therapies. The Hereditary angioedema companies which have their Hereditary angioedema drug candidates in the most advanced stage, i.e. Phase III include KalVista Pharmaceuticals.

 

Learn more about the emerging Hereditary Angioedema Pipeline Therapies @ Hereditary Angioedema Clinical Trials Assessment

 

Scope of the Hereditary Angioedema Pipeline Report

• Coverage- Global
• Hereditary Angioedema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Hereditary Angioedema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Hereditary Angioedema Companies- BioCryst Pharmaceuticals, KalVista Pharmaceuticals, Pharvaris, BioMarin Pharmaceutical, Ionis Pharmaceuticals, Inc., Intellia Therapeutics, and others.
• Hereditary Angioedema Pipeline Therapies- DX-2930 – 300mg/2wk, Icatibant, Donidalorsen, STAR-0215, ADX-324, TAK-743 300 mg, and others.

 

Dive deep into rich insights for new drugs for Hereditary Angioedema treatment, Visit @ Hereditary Angioedema Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Hereditary angioedema Executive Summary
3. Hereditary angioedema: Overview
4. Hereditary angioedema Pipeline Therapeutics
5. Hereditary angioedema Therapeutic Assessment
6. Hereditary angioedema – DelveInsight’s Analytical Perspective
7. In-depth Commercial Assessment
8. Hereditary angioedema Collaboration Deals
9. Late Stage Products (Phase III and NDA)
10. KVD900: KalVista Pharmaceuticals
11. Mid Stage Products (Phase II)
12. PHA121: Pharvaris
13. Drug profiles in the detailed report…..
14. Early Stage Products (Phase I)
15. BMN 331: BioMarin Pharmaceutical
16. Drug profiles in the detailed report…..
17. Pre-clinical and Discovery Stage Products
18. Drug Name: Company Name
19. Inactive Products
20. Hereditary angioedema Key Companies
21. Hereditary angioedema Key Products
22. Hereditary angioedema- Unmet Needs
23. Hereditary angioedema- Market Drivers and Barriers
24. Hereditary angioedema- Future Perspectives and Conclusion
25. Hereditary angioedema Analyst Views
26. Hereditary angioedema Key Companies
27. Appendix

 

For further information on the Hereditary Angioedema pipeline therapeutics, reach out to Hereditary Angioedema Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking